Skip to content
MarketScale
‹ Back to IndustriesSciences

The Secret Science To Harnessing the Power of Probiotics using Prebiotics

The podcast discusses the importance of prebiotics in enhancing the efficacy of probiotics for gut health. With insights from Deerland Probiotics & Enzymes, it highlights the science, consumer habits, and the challenges in marketing prebiotics effectively. Key developments include Deerland's breakthrough in reducing required prebiotic dosage for beneficial effects.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Daniel Litwin · Daniel Litwin PodcastJohn Davidson PodcastJohn Deaton PodcastPromoted Content
Share
The Secret Science To Harnessing the Power of Probiotics using Prebiotics

Key takeaways

01

Prebiotics are essential for maximizing the benefits of probiotics in gut health.

02

Deerland has developed a prebiotic that requires only 15 mg per day for efficacy.

03

Consumer education on prebiotics is critical as the market for digestive health products grows.

Whether you prefer yogurt, kimchi, kefir, or kombucha, probiotics are all around us. But how do we really harness the benefits of this good bacteria, and capitalize on consuming foods that keep us healthy? The answer — Prebiotics.

Tackling the science, consumer habits, and marketing behind prebiotics in this episode of the MarketScale Sciences Podcast are scientists John Davidson, Director of Innovation & Education for Deerland Probioics & Enzymes, and John Deaton, VP of Science & Technology for Deerland Probiotics & Enzymes. This episode talks about how and why it is important to prime your gut with prebiotics, in order to truly harness the power of probiotics. From a marketing standpoint “probiotics were first out of the gate,” Deaton says, “but it’s not as simple as consuming a probiotic.”

Probiotic organisms are not very shelf-stable, nor very resilient to our stomach acids. This is why a prebiotic is so important. As non-living organisms, prebiotics are a food source or a compound, and much easier to manage in application. But, for real efficacy, prebiotics must be consumed in large doses. Herein lies the crux that Deerland has tackled head-on.

How do we provide a prebiotic that is small, consumable, and reduces the main side effect of gas, caused by fermentation in the gut? Davidson explains the groundbreaking science of their prebiotic, which is “based on bacteria phase technology.” Davidson and Deaton have reduced the dosage of necessary prebiotics from over 1 gram, to “Only 15 mg a day required for efficacy.”

In short, Deerland has “Really revolutionized the whole prebiotic space.” Says Davidson. The science is in, but the hard work isn’t over. “Consumer education is gonna be the key,” says Davidson. Consumers may love the idea of probiotics, but don’t know that their efforts are futile without the symbiotic help of prebiotics.

Luckily, the probiotic and prebiotic markets are only growing, with business owners taking note of this health phenomenon. Deerland Probiotics & Enzymes is ready with their prebiotic solution, PreforPro.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @HealthMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

Daniel Litwin
Daniel LitwinEditor, B2B Media, MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics has hired Neil Anderson, Ph.D. as the Chief Revenue Officer to spearhead the commercialization of its nanoimprint flat optics platform. The platform is intended for use in AI datacenters, augmented reality (AR), and life sciences applications. Anderson's experience in photonics is expected to aid Myrias Optics in expanding its market presence in these sectors.

  • 01Myrias Optics appointed Neil Anderson, Ph.D. as CRO to lead the commercialization of its technology.
  • 02The company focuses on nanoimprint flat optics for AI datacenters, AR, and life sciences.
  • 03Neil Anderson brings extensive photonics expertise to support Myrias Optics' growth.

Jul 31, 2026

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

Daniel Litwin
Daniel Litwin

Editor, B2B Media

MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

JD
John Davidson

Director of Innovation & Education

Deerland Probiotics & Enzymes

John Davidson is the Director of Innovation & Education at Deerland Probiotics & Enzymes. He focuses on advancing the understanding and application of probiotics and prebiotics in the health market.

JD
John Deaton

VP of Science & Technology

Deerland Probiotics & Enzymes

John Deaton is the Vice President of Science & Technology at Deerland Probiotics & Enzymes, where he leads scientific efforts to improve probiotics' efficacy with innovative prebiotic solutions.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512